10.1016/j.neulet.2007.01.004 132
Classified as an investigational new drug, available only within clinical trials Not approved for medical use in humans outside of research protocols Cannot be legally prescribed, dispensed, or marketed for therapeutic purposes Federal law explicitly prohibits use in compounded medications under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act WADA Prohibition Status Based on WADAs prohibition categories: GLP3 likely falls under Section S0 (Non-Approved Substances) of the WADA Prohibited List, which includes: Any pharmacological substance not approved by governmental regulatory health authorities for human therapeutic use Drugs under preclinical or clinical development Substances without current regulatory approval from any health authority worldwide Implications for competitive athletes: Prohibited at all times (in-competition and out-of-competition) No Therapeutic Use Exemptions available for unapproved substances Use could result in anti-doping rule violations and sanctions Detection methods under development as clinical trials progress Research Classification: GLP3 is not intended for commercial sale, medical use outside research protocols, veterinary applications, or dietary supplement formulations
Do not quit
10.1097/00004728-198807000-00019 69 HendersonS
Mizuno T, Cloyd JM, Vicente D, Omichi K, Chun YS, Kopetz SE , Maru D, Conrad C, Tzeng CD, Wei SH, Aloia TA, Vauthey JN
FDA approval for Zepbound in treating sleep apnea was based on two previous Eli Lilly-sponsored trials published in the New England Journal of Medicine involving nearly 470 participants, some of whom were using continuous positive airway pressure (CPAP) machines, a standard treatment for OSA
